Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 3
1997 1
1998 6
1999 1
2000 5
2001 12
2002 11
2003 11
2004 4
2005 10
2006 15
2007 14
2008 14
2009 19
2010 15
2011 13
2012 11
2013 11
2014 15
2015 15
2016 16
2017 14
2018 1
2019 4
2020 6
2021 7
2022 5
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

236 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, Bowen JD, Negroski D, Naismith RT, Hunter SF, Gudesblatt M, Chen H, Lyons J, Shankar SL, Kapadia S, Mendoza JP, Singer BA. Wray S, et al. Adv Ther. 2022 Apr;39(4):1810-1831. doi: 10.1007/s12325-022-02068-7. Epub 2022 Feb 24. Adv Ther. 2022. PMID: 35211872 Free PMC article. Clinical Trial.
Safety and efficacy were evaluated in a subset of newly enrolled patients who had received prior glatiramer acetate (GA; GA/DRF) or interferons (IFN; IFN/DRF) as their most recent DMT, prior to switching to DRF in EVOLVE-MS-1. ...
Safety and efficacy were evaluated in a subset of newly enrolled patients who had received prior glatiramer acetate (GA; GA/DR …
Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial.
Cheshmavar M, Mirmosayyeb O, Badihian N, Badihian S, Shaygannejad V. Cheshmavar M, et al. Acta Neurol Scand. 2021 Feb;143(2):178-187. doi: 10.1111/ane.13344. Epub 2020 Oct 27. Acta Neurol Scand. 2021. PMID: 32897569 Clinical Trial.
BACKGROUND: Treatment options for secondary progressive multiple sclerosis (SPMS) are limitedly investigated. We aimed to compare the efficacy of rituximab (RTX) and glatiramer acetate (GA) in SPMS patients. METHOD: This open, randomized clinical trial was conducted …
BACKGROUND: Treatment options for secondary progressive multiple sclerosis (SPMS) are limitedly investigated. We aimed to compare the effica …
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.
Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, Hambraeus J, Axelsson M, Nimer FA, Sundström P, Gunnarsson M, Johansson R, Mellergård J, Rosenstein I, Ayad A, Sjöblom I, Risedal A, de Flon P, Gilland E, Lindeberg J, Shawket F, Piehl F, Lycke J. Svenningsson A, et al. Lancet Neurol. 2022 Aug;21(8):693-703. doi: 10.1016/S1474-4422(22)00209-5. Lancet Neurol. 2022. PMID: 35841908 Clinical Trial.
Key inclusion criteria for participants were: age 18-50 years; relapsing-remitting multiple sclerosis or clinically isolated syndrome according to prevailing McDonald criteria; 10 years or less since diagnosis; untreated or only exposed to interferons or glatiramer acet …
Key inclusion criteria for participants were: age 18-50 years; relapsing-remitting multiple sclerosis or clinically isolated syndrome accord …
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Free article. Clinical Trial.
An active agent, glatiramer acetate, was also included as a reference comparator. The primary end point was the annualized relapse rate over a period of 2 years. The study was not designed to test the superiority or noninferiority of BG-12 versus glatiramer …
An active agent, glatiramer acetate, was also included as a reference comparator. The primary end point was the annualized rel …
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
METHODS: In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on interferon beta or glatiramer. Eligible participants were randomly allocated in a 1:2:2 ra …
METHODS: In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-55 years with relapsing-remitting mult …
Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis.
Dolladille C, Chrétien B, Peyro-Saint-Paul L, Alexandre J, Dejardin O, Fedrizzi S, Defer G. Dolladille C, et al. Neurotherapeutics. 2021 Jul;18(3):1657-1664. doi: 10.1007/s13311-021-01073-y. Epub 2021 Jul 6. Neurotherapeutics. 2021. PMID: 34231126 Free PMC article. Clinical Trial.
All consecutive reports of DMTs prescribed to pwMS (alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon-beta, natalizumab, ocrelizumab, and teriflunomide), and their serious adverse event cases were eligible, excluding those reporting immunosu …
All consecutive reports of DMTs prescribed to pwMS (alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon …
United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
Wolinsky JS, Narayana PA, Johnson KP; Multiple Sclerosis Study Group and the MRI Analysis Center. Wolinsky JS, et al. Mult Scler. 2001 Feb;7(1):33-41. doi: 10.1177/135245850100700107. Mult Scler. 2001. PMID: 11321192 Clinical Trial.
At imaging, 66 patients originally randomized to placebo (oPBO) in the pivotal trial had received glatiramer acetate for 1,476 +/- 63 days, and 69 randomized to active treatment with glatiramer acetate (oGA) were on drug for 2,433 +/- 59 days. ...These …
At imaging, 66 patients originally randomized to placebo (oPBO) in the pivotal trial had received glatiramer acetate for 1,476 …
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberyé J, van den Tweel E, Mulder R, Koper N, Voortman G, Barkhof F; Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group. Cohen J, et al. JAMA Neurol. 2015 Dec;72(12):1433-41. doi: 10.1001/jamaneurol.2015.2154. JAMA Neurol. 2015. PMID: 26458034 Clinical Trial.
IMPORTANCE: The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity to develop generic alternatives. OBJECTIVE: To evaluate in the Glatiramer Acetate Clinical Trial to Assess Equivalence With Co …
IMPORTANCE: The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity …
The PROMiSe trial: baseline data review and progress report.
Wolinsky JS; PROMiSe Trial Study Group. Wolinsky JS, et al. Mult Scler. 2004 Jun;10 Suppl 1:S65-71; discussion S71-2. doi: 10.1177/135245850401000112. Mult Scler. 2004. PMID: 15218813 Review.
The PROMiSe trial is a multinational, multicentre, double-blind, placebo-controlled trial evaluating the effects of glatiramer acetate treatment over 3 years in patients with primary progressive multiple sclerosis (PPMS). ...
The PROMiSe trial is a multinational, multicentre, double-blind, placebo-controlled trial evaluating the effects of glatiramer ace …
236 results